

Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

ScienceDirect

journal homepage: <http://www.elsevier.com/locate/crvasa>

## Guidelines

# 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS Summary of the document prepared by the Czech Society of Cardiology<sup>☆</sup>

Robert Čihák<sup>a</sup>, Luděk Haman<sup>b</sup>, Miloš Táborský<sup>c,\*</sup>

<sup>a</sup> Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

<sup>b</sup> Department of Cardiovascular Medicine, University Hospital, Hradec Kralove, Czech Republic

<sup>c</sup> Department of Internal Medicine I – Cardiology, University Hospital Olomouc, 775 20 Olomouc, Czech Republic

Authors of the original ESC full text document [1]: Paulus Kirchhof, Stefano Benussi on behalf of The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC).

## ARTICLE INFO

### Article history:

Received 19 September 2016

Received in revised form

4 November 2016

Accepted 7 November 2016

Available online xxx

### Keywords:

Guidelines

Atrial fibrillation

Anticoagulation

Vitamin K antagonists

Non-vitamin K antagonist oral

anticoagulants

Left atrial appendage occlusion

Rate control

Cardioversion

Rhythm control

Antiarrhythmic drugs

Upstream therapy

<sup>☆</sup> For permissions: please e-mail: [guidelines@escardio.org](mailto:guidelines@escardio.org).

\* Corresponding author.

E-mail address: [milos.taborsky@seznam.cz](mailto:milos.taborsky@seznam.cz) (M. Táborský).

<http://dx.doi.org/10.1016/j.crvasa.2016.11.005>

0010-8650/© 2016 Published by Elsevier Sp. z o.o. on behalf of The Czech Society of Cardiology.

Catheter ablation  
 AF surgery  
 Valve repair  
 Pulmonary vein isolation  
 Left atrial ablation



EUROPEAN  
 SOCIETY OF  
 CARDIOLOGY®

ČESKÁ KARDIOLOGICKÁ SPOLEČNOST  
 THE CZECH SOCIETY OF CARDIOLOGY

## Contents

1. Preamble	000
2. Introduction	000
3. Epidemiology and impact for patients	000
3.1. Incidence and prevalence of atrial fibrillation	000
3.2. Morbidity, mortality, and healthcare burden of atrial fibrillation	000
3.3. Impact of evidence-based management on outcomes in atrial fibrillation patients	000
3.4. Gender	000
4. Pathophysiological and genetic aspects that guide management	000
4.1. Genetic predisposition	000
4.2. Mechanisms leading to atrial fibrillation	000
4.2.1. Remodelling of atrial structure and ion channel function	000
4.2.2. Electrophysiological mechanisms of atrial fibrillation	000
5. Diagnosis and timely detection of atrial fibrillation	000
5.1. Overt and silent atrial fibrillation	000
5.2. Screening for silent atrial fibrillation	000
5.3. Electrocardiogram detection of atrial flutter	000
6. Classification of atrial fibrillation	000
6.1. Atrial fibrillation pattern	000
6.2. Atrial fibrillation types reflecting different causes of the arrhythmia	000
6.3. Symptom burden in atrial fibrillation	000
7. Detection and management of risk factors and concomitant cardiovascular diseases	000
7.1. Heart failure	000
7.1.1. Patients with atrial fibrillation and heart failure with reduced ejection fraction	000
7.1.2. Atrial fibrillation patients with heart failure with preserved ejection fraction	000
7.1.3. Atrial fibrillation patients with heart failure with mid-range ejection fraction	000
7.1.4. Prevention of atrial fibrillation in heart failure	000
7.2. Hypertension	000
7.3. Valvular heart disease	000
7.4. Diabetes mellitus	000
7.5. Obesity and weight loss	000
7.6. Chronic obstructive pulmonary disease, sleep apnoea, and other respiratory diseases	000
7.7. Chronic kidney disease	000
8. Integrated management of patients with atrial fibrillation	000
8.1. Diagnostic workup of atrial fibrillation patients	000
8.1.1. Recommended evaluation in all atrial fibrillation patients	000
8.1.2. Additional investigations in selected patients with atrial fibrillation	000
8.2. Structured follow-up	000
8.3. Defining goals of atrial fibrillation management	000
9. Stroke prevention therapy in atrial fibrillation patients	000
9.1. Prediction of stroke and bleeding risk	000
9.1.1. Anticoagulation in patients with a CHA <sub>2</sub> DS <sub>2</sub> -VASC score of 1 in men and 2 in women	000
9.1.2. Clinical risk scores for bleeding	000
9.2. Stroke prevention	000
9.2.1. Vitamin K antagonists	000
9.2.2. Non-vitamin K antagonist oral anticoagulants	000
9.2.3. Oral anticoagulation in atrial fibrillation patients with chronic kidney disease	000
9.2.4. Antiplatelet therapy as an alternative to oral anticoagulants	000

Download English Version:

<https://daneshyari.com/en/article/5577799>

Download Persian Version:

<https://daneshyari.com/article/5577799>

[Daneshyari.com](https://daneshyari.com)